{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:22:28Z","timestamp":1793161348779,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-025-04525-z","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T13:35:34Z","timestamp":1773063334000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of RET inhibitors in the management of advanced, RET mutated, pheochromocytoma. Pooled analysis of published cases with the addition of 2 new cases"],"prefix":"10.1007","volume":"91","author":[{"given":"Valentina","family":"Cremaschi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Lagan\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Turla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Dondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Trevisan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Giacch\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Grisanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Zilioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bertagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Berruti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Cosentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"issue":"11","key":"4525_CR1","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","volume":"31","author":"M Fassnacht","year":"2020","unstructured":"M. Fassnacht et al., Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 31(11), 1476\u20131490 (2020)","journal-title":"Ann. Oncol."},{"issue":"2","key":"4525_CR2","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/ncpendmet0396","volume":"3","author":"K. Pacak","year":"2007","unstructured":"K. Pacak et al., Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab, 2007. 3(2):92\u2013102","journal-title":"Nat Clin Pract Endocrinol Metab"},{"issue":"2","key":"4525_CR3","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1210\/endrev\/bnab019","volume":"43","author":"S N\u00f6lting","year":"2022","unstructured":"S. N\u00f6lting et al., Personalized management of pheochromocytoma and paraganglioma. Endocr. Rev. 43(2), 199\u2013239 (2022)","journal-title":"Endocr. Rev."},{"issue":"5196","key":"4525_CR4","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1126\/science.7824936","volume":"267","author":"M Santoro","year":"1995","unstructured":"M. Santoro et al., Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science. 267(5196), 381\u2013383 (1995)","journal-title":"Science"},{"issue":"4965","key":"4525_CR5","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1126\/science.2134734","volume":"249","author":"MR Wallace","year":"1990","unstructured":"M.R. Wallace et al., Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science. 249(4965), 181\u2013186 (1990)","journal-title":"Science"},{"issue":"3","key":"4525_CR6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/ng.533","volume":"42","author":"Y Qin","year":"2010","unstructured":"Y. Qin et al., Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nat. Genet. 42(3), 229\u2013233 (2010)","journal-title":"Nat. Genet."},{"issue":"7","key":"4525_CR7","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/ng.861","volume":"43","author":"I Comino-M\u00e9ndez","year":"2011","unstructured":"I. Comino-M\u00e9ndez et al., Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat. Genet. 43(7), 663\u2013667 (2011)","journal-title":"Nat. Genet."},{"issue":"10","key":"4525_CR8","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1158\/1078-0432.CCR-12-0160","volume":"18","author":"N Burnichon","year":"2012","unstructured":"N. Burnichon et al., MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin. Cancer Res. 18(10), 2828\u20132837 (2012)","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"4525_CR9","doi-asserted-by":"publisher","first-page":"E1266","DOI":"10.1210\/jc.2012-4257","volume":"98","author":"J Crona","year":"2013","unstructured":"J. Crona et al., Somatic mutations in H-RAS in sporadic pheochromocytoma and paraganglioma identified by exome sequencing. J. Clin. Endocrinol. Metab. 98(7), E1266\u2013E1271 (2013)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"4525_CR10","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","volume":"31","author":"L Fishbein","year":"2017","unstructured":"L. Fishbein et al., Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell. 31(2), 181\u2013193 (2017)","journal-title":"Cancer Cell."},{"issue":"6","key":"4525_CR11","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1210\/jc.2014-1498","volume":"99","author":"JW Lenders","year":"2014","unstructured":"J.W. Lenders et al., Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 99(6), 1915\u20131942 (2014)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"25","key":"4525_CR12","doi-asserted-by":"publisher","first-page":"4162","DOI":"10.1200\/JCO.2008.21.3496","volume":"27","author":"S Gonias","year":"2009","unstructured":"S. Gonias et al., Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J. Clin. Oncol. 27(25), 4162\u20134168 (2009)","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"4525_CR13","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2967\/jnumed.118.217463","volume":"60","author":"DA Pryma","year":"2019","unstructured":"D.A. Pryma et al., Efficacy and safety of High-Specific-Activity. J. Nucl. Med. 60(5), 623\u2013630 (2019)","journal-title":"J. Nucl. Med."},{"issue":"9","key":"4525_CR14","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1210\/jc.2017-00816","volume":"102","author":"G Kong","year":"2017","unstructured":"G. Kong et al., Efficacy of peptide receptor radionuclide therapy for functional metastatic paraganglioma and pheochromocytoma. J. Clin. Endocrinol. Metab. 102(9), 3278\u20133287 (2017)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"11","key":"4525_CR15","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1002\/ijc.28913","volume":"135","author":"J Hadoux","year":"2014","unstructured":"J. Hadoux et al., SDHB mutations are associated with response to Temozolomide in patients with metastatic pheochromocytoma or paraganglioma. Int. J. Cancer. 135(11), 2711\u20132720 (2014)","journal-title":"Int. J. Cancer"},{"issue":"11","key":"4525_CR16","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1002\/cncr.26577","volume":"118","author":"M Ayala-Ramirez","year":"2012","unstructured":"M. Ayala-Ramirez et al., Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience. Cancer. 118(11), 2804\u20132812 (2012)","journal-title":"Cancer"},{"issue":"25","key":"4525_CR17","doi-asserted-by":"publisher","first-page":"19297","DOI":"10.1074\/jbc.M905866199","volume":"275","author":"D Califano","year":"2000","unstructured":"D. Califano et al., Signaling through Ras is essential for Ret oncogene-induced cell differentiation in PC12 cells. J. Biol. Chem. 275(25), 19297\u201319305 (2000)","journal-title":"J. Biol. Chem."},{"issue":"5","key":"4525_CR18","doi-asserted-by":"publisher","first-page":"3568","DOI":"10.1074\/jbc.275.5.3568","volume":"275","author":"C Segouffin-Cariou","year":"2000","unstructured":"C. Segouffin-Cariou, M. Billaud, Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase\/AKT signaling pathway. J. Biol. Chem. 275(5), 3568\u20133576 (2000)","journal-title":"J. Biol. Chem."},{"issue":"11","key":"4525_CR19","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1200\/JCO.19.02551","volume":"38","author":"V Subbiah","year":"2020","unstructured":"V. Subbiah et al., State-of-the-Art strategies for targeting. J. Clin. Oncol. 38(11), 1209\u20131221 (2020)","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"4525_CR20","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.annonc.2020.11.021","volume":"32","author":"C Belli","year":"2021","unstructured":"C. Belli et al., ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research. Ann. Oncol. 32(3), 337\u2013350 (2021)","journal-title":"Ann. Oncol."},{"issue":"12","key":"4525_CR21","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.trecan.2021.07.003","volume":"7","author":"KZ Thein","year":"2021","unstructured":"K.Z. Thein et al., Precision therapy for RET-altered cancers with RET inhibitors. Trends Cancer. 7(12), 1074\u20131088 (2021)","journal-title":"Trends Cancer"},{"issue":"9","key":"4525_CR22","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2005653","volume":"383","author":"A Drilon","year":"2020","unstructured":"A. Drilon et al., Efficacy of Selpercatinib in. N Engl. J. Med. 383(9), 813\u2013824 (2020)","journal-title":"N Engl. J. Med."},{"issue":"9","key":"4525_CR23","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1056\/NEJMoa2005651","volume":"383","author":"LJ Wirth","year":"2020","unstructured":"L.J. Wirth et al., Efficacy of Selpercatinib in. N Engl. J. Med. 383(9), 825\u2013835 (2020)","journal-title":"N Engl. J. Med."},{"issue":"10","key":"4525_CR24","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","volume":"23","author":"V Subbiah","year":"2022","unstructured":"V. Subbiah et al., Tumour-agnostic efficacy and safety of Selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial. Lancet Oncol. 23(10), 1261\u20131273 (2022)","journal-title":"Lancet Oncol."},{"issue":"7","key":"4525_CR25","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/S1470-2045(21)00247-3","volume":"22","author":"JF Gainor","year":"2021","unstructured":"J.F. Gainor et al., Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1\/2 study. Lancet Oncol. 22(7), 959\u2013969 (2021)","journal-title":"Lancet Oncol."},{"issue":"8","key":"4525_CR26","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S2213-8587(21)00120-0","volume":"9","author":"V Subbiah","year":"2021","unstructured":"V. Subbiah et al., Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1\/2 study. Lancet Diabetes Endocrinol. 9(8), 491\u2013501 (2021)","journal-title":"Lancet Diabetes Endocrinol."},{"key":"4525_CR27","doi-asserted-by":"crossref","unstructured":"B. Konda et al., Clinical activity of Selpercatinib in RET mutant Pheochromocytoma-Case reports. J. Endocr. Soc., 5(1) A994 (2021)","DOI":"10.1210\/jendso\/bvab048.2034"},{"key":"4525_CR28","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1200\/PO.21.00127","volume":"5","author":"A. Mweempwa","year":"2021","unstructured":"A. Mweempwa, H. Xu, J.H.A. Vissers, R.W. Tothill, A.D. Pattison, A.P. Fellowes, D.M. Thomas, G. Richardson, R.J. Hicks, S.M. Grimmond, S.B. Fox, S.J. Luen, J. Desai, B.J. Solomon, R.E.T. Novel, Fusion, RET-SEPTIN9 Predicts Response to Selective RET Inhibition With Selpercatinib in Malignant Pheochromocytoma. JCO Precis Oncol. 5, 1160\u20131165 (2021) https:\/\/doi.org\/10.1200\/PO.21.00127","journal-title":"JCO Precis Oncol."},{"issue":"3","key":"4525_CR29","doi-asserted-by":"publisher","first-page":"e600","DOI":"10.1210\/clinem\/dgae283","volume":"110","author":"B Deschler-Baier","year":"2025","unstructured":"B. Deschler-Baier, B. Konda, E. Massarelli, M.I. Hu, L.J. Wirth, X. Xu, J. Wright, R.J. Clifton-Bligh, Clinical activity of Selpercatinib in RET-mutant pheochromocytoma. J. Clin. Endocrinol. Metab. 110(3), e600\u2013e606 (2025). https:\/\/doi.org\/10.1210\/clinem\/dgae283. PMID: 38661071; PMCID: PMC11834701","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"12","key":"4525_CR30","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1007\/s11864-023-01145-5","volume":"24","author":"M Lagan\u00e0","year":"2023","unstructured":"M. Lagan\u00e0 et al., The evolving treatment landscape of medullary thyroid cancer. Curr. Treat. Options Oncol. 24(12), 1815\u20131832 (2023)","journal-title":"Curr. Treat. Options Oncol."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04525-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-025-04525-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04525-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T13:35:35Z","timestamp":1773063335000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-025-04525-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4525"],"URL":"https:\/\/doi.org\/10.1007\/s12020-025-04525-z","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"20 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from the two patients treated in our Institution.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate and consent to publish"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"91"}}